T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIRX
1076
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $22.9M | ﹤0.01% |
16,730
+60
| +0.4% | +$69.6K |
|
1077
NewMarket
NEU
$8.72B
| $22.8M | ﹤0.01% |
58,100
-88,555
| -60% | -$34.1M |
|
|
MEAS
1078
DELISTED
MEASUREMENT SPECIALTIES INC
MEAS
| $22.8M | ﹤0.01% |
264,630
-1,000
| -0.4% | -$69.2K |
|
|
NEWP
1079
DELISTED
NEWPORT CORP
NEWP
| $22.7M | ﹤0.01% |
1,229,090
-1,200
| -0.1% | -$22.4K |
|
1080
Golub Capital BDC
GBDC
$3.48B
| $22.7M | ﹤0.01% |
1,311,526
+168,425
| +15% | +$2.81M |
|
1081
American Public Education
APEI
$826M
| $22.7M | ﹤0.01% |
659,810
-748,726
| -53% | -$26.1M |
|
1082
iShares MSCI Taiwan ETF
EWT
$11.6B
| $22.7M | ﹤0.01% |
+717,500
| New | +$21.5M |
|
1083
Ralph Lauren
RL
$23.6B
| $22.7M | ﹤0.01% |
141,054
-189,957
| -57% | -$29.3M |
|
1084
Culp Inc
CULP
$43.8M
| $22.7M | ﹤0.01% |
1,301,200
-300
| -0% | -$5.48K |
|
1085
Lincoln National
LNC
$8.44B
| $22.6M | ﹤0.01% |
440,275
+31,200
| +8% | +$1.54M |
|
1086
Tyler Technologies
TYL
$13B
| $22.6M | ﹤0.01% |
248,200
+9,500
| +4% | +$770K |
|
1087
Principal Financial Group
PFG
$24.4B
| $22.6M | ﹤0.01% |
447,860
+27,400
| +7% | +$1.29M |
|
|
ROIC
1088
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $22.5M | ﹤0.01% |
1,430,400
+1,411,400
| +7,428% | +$22.1M |
|
1089
KeyCorp
KEY
$24.5B
| $22.5M | ﹤0.01% |
1,569,927
+115,500
| +8% | +$1.6M |
|
|
AZPN
1090
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $22.5M | ﹤0.01% |
484,079
+26,464
| +6% | +$1.23M |
|
1091
Oneok
OKE
$58.3B
| $22.5M | ﹤0.01% |
329,860
-2,810
| -0.8% | -$178K |
|
1092
Groupon
GRPN
$901M
| $22.3M | ﹤0.01% |
168,628
-961,791
| -85% | -$127M |
|
1093
MACOM Technology Solutions
MTSI
$23.5B
| $22.3M | ﹤0.01% |
992,670
-131,310
| -12% | -$2.53M |
|
|
RSPP
1094
DELISTED
RSP Permian, Inc.
RSPP
| $22.2M | ﹤0.01% |
684,950
-351,310
| -34% | -$10M |
|
1095
Ironwood Pharmaceuticals
IRWD
$714M
| $22.2M | ﹤0.01% |
1,727,361
-477,642
| -22% | -$5.19M |
|
|
ANDV
1096
DELISTED
Andeavor
ANDV
| $22.1M | ﹤0.01% |
376,823
-72,290
| -16% | -$3.99M |
|
|
ESV
1097
DELISTED
Ensco Rowan plc
ESV
| $22M | ﹤0.01% |
99,098
+9,025
| +10% | +$1.87M |
|
|
PPS
1098
DELISTED
Post Properties
PPS
| $21.9M | ﹤0.01% |
410,488
-10,631
| -3% | -$545K |
|
1099
Helmerich & Payne
HP
$4.29B
| $21.8M | ﹤0.01% |
187,966
-2,700
| -1% | -$296K |
|
|
SLXP
1100
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $21.8M | ﹤0.01% |
176,873
+13,900
| +9% | +$1.54M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.